Who owns IMMIX BIOPHARMA INC?
- Ticker: IMMX
- CUSIP Number: 45258h106
Tip: Access positions for across all investors
Analyze quarterly positions in Immix Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Immix Biopharma stock
Who bought or sold IMMIX BIOPHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Saturn V Capital Management | 3.0M | $16M | 100% | Dec 2025 |
|
| Eventide Asset Management | 2.5M | $13M | 100% | Dec 2025 |
|
| Marshall Wace | 2.0M | $10M | 3495% | Dec 2025 |
|
| Vanguard Group | 1.1M | $5.7M | 50% | Dec 2025 |
|
| Logos Global Management | 1.0M | $5.2M | 100% | Dec 2025 |
|
| Bleichroeder | 1.0M | $5.2M | 18% | Dec 2025 |
|
| Blue Owl Capital Holdings | 986k | $5.2M | 100% | Dec 2025 |
|
| Franklin Resources | 980k | $5.1M | 100% | Dec 2025 |
|
| Susquehanna International | 482k | $2.5M | 431% | Dec 2025 |
|
| Ameriprise Financial | 452k | $2.4M | 100% | Dec 2025 |
|
| Burkehill Global Management | 294k | $1.5M | 100% | Dec 2025 |
|
| Renaissance Technologies | 259k | $1.4M | 1103% | Dec 2025 |
|
| Geode Capital Management | 246k | $1.3M | 31% | Dec 2025 |
|
| KVP Capital Advisors | 230k | $1.2M | 100% | Dec 2025 |
|
| Goldman Sachs Group | 208k | $1.1M | 100% | Dec 2025 |
|
| Jane Street | 167k | $874k | 1016% | Dec 2025 |
|
| BlackRock | 130k | $681k | 202% | Dec 2025 |
|
| LGT Fund Management | 125k | $660k | 100% | Dec 2025 |
|
| Eudaimonia Asset Management | 121k | $632k | 100% | Dec 2025 |
|
| J. Goldman & Co | 118k | $619k | 100% | Dec 2025 |
|
| Northern Trust | 101k | $526k | 13% | Dec 2025 |
|
| Bank of New York Mellon | 99k | $516k | 100% | Dec 2025 |
|
| State Street Corporation | 97k | $509k | -2% | Dec 2025 |
|
| Citadel Advisors | 90k | $188k | 100% | Sep 2025 |
|
| OMERS Administration Corporation | 75k | $391k | 100% | Dec 2025 |
|
| Virtu Financial | 74k | $386k | 100% | Dec 2025 |
|
| Sei Investments | 74k | $385k | 100% | Dec 2025 |
|
| United Capital Financial Advisers | 71k | $148k | 100% | Sep 2025 |
|
| Tocqueville Asset Management | 69k | $359k | 70% | Dec 2025 |
|
| UBS Group | 59k | $307k | 2921% | Dec 2025 |
|
| ADAR1 Capital Management | 50k | $262k | 100% | Dec 2025 |
|
| Qube Research & Technologies | 50k | $261k | 100% | Dec 2025 |
|
| XTX Topco | 46k | $243k | 32% | Dec 2025 |
|
| Atlantic Trust | 40k | $209k | 300% | Dec 2025 |
|
| Barclays | 35k | $183k | 100% | Dec 2025 |
|
| Velan Capital Investment Management | 35k | $183k | 0% | Dec 2025 |
|
| Jump Financial | 34k | $177k | 100% | Dec 2025 |
|
| Hudson Bay Capital Management | 34k | $176k | 100% | Dec 2025 |
|
| Persistent Asset Partners | 32k | $166k | 100% | Dec 2025 |
|
| Private Advisor | 32k | $166k | 2% | Dec 2025 |
|
| Concurrent Investment Advisors | 27k | $144k | 100% | Dec 2025 |
|
| Quadrature Capital | 22k | $116k | 100% | Dec 2025 |
|
| Squarepoint Ops | 22k | $112k | 100% | Dec 2025 |
|
| Imprint Wealth | 20k | $105k | -70% | Dec 2025 |
|
| Kera Capital Partners | 13k | $76k | 100% | Dec 2025 |
|
| Commonwealth Equity Services | 12k | $65k | -23% | Dec 2025 |
|
| Tower Research Capital | 12k | $64k | 100% | Dec 2025 |
|
| Mathes Company | 11k | $56k | 100% | Dec 2025 |
|
| Lighthouse Investment Partners | 10k | $52k | 100% | Dec 2025 |
|
| Snowden Capital Advisors | 10k | $52k | 0% | Dec 2025 |
|
| SBI Securities | 10k | $52k | -43% | Dec 2025 |
|
| Hanson McClain Advisors | 5.7k | $30k | 100% | Dec 2025 |
|
| Bnp Paribas Arbitrage, Snc | 2.7k | $14k | 100% | Dec 2025 |
|
| CWM | 1.0k | $5.0k | 100% | Dec 2025 |
|
| Northwestern Mutual Wealth Management Company | 3.00 | $15.999900 | -96% | Dec 2025 |
|
Who sold out of Immix Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Tritonpoint Wealth | Sep 2025 | 25k | $51k |
| Colony | Sep 2025 | 12k | $25k |
| Royal Bank of Canada | Jun 2025 | 11k | $23k |
| MAI Wealth Advisors | Sep 2025 | 2.0k | $4.2k |
| Wells Fargo & Company | Sep 2025 | 330.00 | $689.997000 |
| SRS Capital Advisors | Sep 2025 | 34.00 | $70.998800 |